Patents by Inventor Masahiro Neya
Masahiro Neya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11891412Abstract: The purpose of the present invention is to provide a method for purifying and preparing a highly liposoluble phosphoramidite, as well as a capping reaction using the highly liposoluble phosphoramidite compound, and as well as a method for preparing oligonucleotide by a liquid phase process using a pseudo solid phase protecting group said method comprising the capping reaction step.Type: GrantFiled: December 26, 2018Date of Patent: February 6, 2024Assignee: KNC LABORATORIES CO., LTD.Inventors: Tsuyoshi Fujihara, Kenichi Nakamura, Toru Kurome, Daisuke Sasahara, Akiko Shimahara, Masahiro Neya
-
Publication number: 20230272403Abstract: An antisense oligonucleotide is provided which induces exon skipping in ACE2 gene. An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target site in exon 18 of angiotensin-converting enzyme 2 gene and is capable of inducing exon skipping in angiotensin-converting enzyme 2 gene. A pharmaceutical drug comprising the antisense oligonucleotide or a salt or a solvate thereof; and an agent for inhibiting the expression of angiotensin-converting enzyme 2 protein and/or for enhancing the expression of soluble angiotensin-converting enzyme 2.Type: ApplicationFiled: July 19, 2021Publication date: August 31, 2023Applicants: KNC LABORATORIES CO., LTD., KOBE GAKUIN EDUCATIONAL FOUNDATIONInventors: Masafumi MATSUO, Kazuhiro MAETA, Tsuyoshi FUJIHARA, Itaru OKAMOTO, Masahiro NEYA
-
Publication number: 20210230598Abstract: The present invention provides a tau exon 10 skipping-promoting antisense oligonucleotide containing at least one 2?-O, 4?-C-ethylene-bridged nucleic acid, and a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a region consisting of the nucleotide sequence shown in SEQ ID NO: 44 in exon 10 of a tau mRNA precursor. In addition, the present invention provides a tau exon 10 skipping-suppressing antisense oligonucleotide containing at least one 2?-O, 4?-C-ethylene-bridged nucleic acid, and a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a region consisting of the nucleotide sequence shown in SEQ ID NO: 45 in intron 10 of a tau mRNA precursor.Type: ApplicationFiled: July 3, 2019Publication date: July 29, 2021Applicants: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM, KNC LABORATORIES CO., LTD.Inventors: Gen SOBUE, Kentaro SAHASHI, Shinsuke ISHIGAKI, Kuniyuki ENDO, Tsuyoshi FUJIHARA, Masahiro NEYA, Seiji MATSUDA
-
Patent number: 11028390Abstract: The present invention provides a suppression type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in any of SEQ ID NOs: 2-4, and a promotion type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in SEQ ID NO: 5.Type: GrantFiled: July 6, 2018Date of Patent: June 8, 2021Assignees: Osaka University, KNC Laboratories Co., Ltd., Aichi Medical UniversityInventors: Yoshitaka Nagai, Kazuhiro Maeta, Toshihide Takeuchi, Masahiro Neya, Tsuyoshi Fujihara, Seiji Matsuda, Gen Sobue, Shinsuke Ishigaki, Kentaro Sahashi
-
Publication number: 20210087220Abstract: The purpose of the present invention is to provide a method for purifying and preparing a highly liposoluble phosphoramidite, as well as a capping reaction using the highly liposoluble phosphoramidite compound, and as well as a method for preparing oligonucleotide by a liquid phase process using a pseudo solid phase protecting group said method comprising the capping reaction step.Type: ApplicationFiled: December 26, 2018Publication date: March 25, 2021Inventors: Tsuyoshi FUJIHARA, Kenichi NAKAMURA, Toru KUROME, Daisuke SASAHARA, Akiko SHIMAHARA, Masahiro NEYA
-
Patent number: 10899790Abstract: Provided are: a compound represented by formula (I); a retinoid metabolic pathway inhibitor comprising the same; an agent for increasing the ratio of memory T cells; a prophylactic and/or therapeutic agent for cancer or an infectious disease; a cancer immunotherapeutic adjuvant; an immunopotentiator; and a method for preparing a T cell population wherein the ratio of memory T cells is increased, said method comprising using the compound of formula (I).Type: GrantFiled: November 8, 2017Date of Patent: January 26, 2021Assignees: OSAKA UNIVERSITY, KNC LABORATORIES CO., LTD.Inventors: Haruo Sugiyama, Fumihiro Fujiki, Masahiro Neya, Shinya Kohno
-
Publication number: 20200165610Abstract: The present invention provides a suppression type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in any of SEQ ID NOs: 2-4, and a promotion type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in SEQ ID NO: 5.Type: ApplicationFiled: July 6, 2018Publication date: May 28, 2020Applicants: OSAKA UNIVERSITY, KNC LABORATORIES CO., LTD., NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITYInventors: Yoshitaka NAGAI, Kazuhiro MAETA, Toshihide TAKEUCHI, Masahiro NEYA, Tsuyoshi FUJIHARA, Seiji MATSUDA, Gen SOBUE, Shinsuke ISHIGAKI, Kentaro SAHASHI
-
Publication number: 20190284228Abstract: Provided are: a compound represented by formula (I); a retinoid metabolic pathway inhibitor comprising the same; an agent for increasing the ratio of memory T cells; a prophylactic and/or therapeutic agent for cancer or an infectious disease; a cancer immunotherapeutic adjuvant; an immunopotentiator; and a method for preparing a T cell population wherein the ratio of memory T cells is increased, said method comprising using the compound of formula (I).Type: ApplicationFiled: November 8, 2017Publication date: September 19, 2019Applicants: OSAKA UNIVERSITY, KNC LABORATORIES CO., LTD.Inventors: Haruo SUGIYAMA, Fumihiro FUJIKI, Masahiro NEYA, Shinya KOHNO
-
Patent number: 9771316Abstract: The invention provides a compound having a selective inhibitory activity against highly-expressed LAT-1 in tumor cell. The compound is represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, and a LAT-1 inhibitor comprising the same.Type: GrantFiled: January 21, 2014Date of Patent: September 26, 2017Assignees: Osaka University, KNC Laboratories Co., Ltd.Inventors: Yoshikatsu Kanai, Shushi Nagamori, Yoshihiko Kitaura, Masahiro Neya, Naohiro Matsushita
-
Publication number: 20150336876Abstract: The invention provides a compound having a selective inhibitory activity against highly-expressed LAT-1 in tumor cell. The compound is represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, and a LAT-1 inhibitor comprising the same.Type: ApplicationFiled: January 21, 2014Publication date: November 26, 2015Inventors: Yoshikatsu KANAI, Shushi NAGAMORI, Yoshihiko KITAURA, Masahiro NEYA, Naohiro MATSUSHITA
-
Patent number: 9056862Abstract: The present invention provides an anticancer drug having a Ras function inhibitory action. The present invention provides a Ras function inhibitor comprising a compound represented by the formula (I?): wherein each symbol is as defined in the present specification, or a salt thereof.Type: GrantFiled: May 9, 2012Date of Patent: June 16, 2015Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, KNC LABORATORIES CO., LTD.Inventors: Tohru Kataoka, Fumi Shima, Masahiro Neya, Daisuke Sasahara
-
Patent number: 8802679Abstract: Compounds of formula (I) defined herein exhibit VAP-1 inhibitory activity, and as a result, are useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention.Type: GrantFiled: September 15, 2010Date of Patent: August 12, 2014Assignee: Astellas Pharma Inc.Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Yuji Koga, Norio Seki, Jiro Fujiyasu, Masahiro Neya
-
Publication number: 20140194412Abstract: The present invention provides an anticancer drug having a Ras function inhibitory action. The present invention provides a Ras function inhibitor comprising a compound represented by the formula (I?): wherein each symbol is as defined in the present specification, or a salt thereof.Type: ApplicationFiled: May 9, 2012Publication date: July 10, 2014Applicants: KNC LABORATORIES CO., LTD., NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITYInventors: Tohru Kataoka, Fumi Shima, Masahiro Neya, Daisuke Sasahara
-
Patent number: 8252895Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.Type: GrantFiled: July 21, 2010Date of Patent: August 28, 2012Assignee: Astellas Pharma Inc.Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
-
Publication number: 20120184520Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.Type: ApplicationFiled: September 15, 2010Publication date: July 19, 2012Applicant: Astellas Pharma Inc.Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Yuji Koga, Norio Seki, Jiro Fujiyasu, Masahiro Neya
-
Patent number: 7872097Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.Type: GrantFiled: October 26, 2006Date of Patent: January 18, 2011Assignee: Astellas Pharma Inc.Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
-
Publication number: 20100286033Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.Type: ApplicationFiled: July 21, 2010Publication date: November 11, 2010Inventors: Masahiro NEYA, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
-
Publication number: 20090170755Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.Type: ApplicationFiled: October 26, 2006Publication date: July 2, 2009Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
-
Patent number: 6967197Abstract: A compound of formula (I) in which R1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R2 is amidated carboxy, R3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor ? (TNF ?)Type: GrantFiled: February 20, 2001Date of Patent: November 22, 2005Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Masahiro Neya, Hitoshi Yamazaki, Kazuhiko Ohne, Yuki Sawada, Tsuyoshi Mizutani, Yoshimasa Imamura, Noriko Mukai
-
Publication number: 20040266826Abstract: A compound of the formula: in which R1 is optionally substituted phenyl, optionally substituted naphthyl, optionally substituted bicyclic heterocyclic group, optionally substituted lower alkenyl or optionally substituted lower alkynyl, and R2 is carboxy or protected carboxy, or a salt thereof, useful for treating and/or preventing MMP- or TNF-&agr; mediated diseases.Type: ApplicationFiled: February 27, 2004Publication date: December 30, 2004Inventors: Masahiro Neya, Akihiko Sawada, Kazuhiko Ohne, Yoshito Abe, Tsuyoshi Mizutani, Naoki Ishibashi, Makoto Inoue